Frost & Sullivan Predicts Growth for the European Vaccines Market
News Feb 01, 2013
As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialization stage, the European vaccines market is expected to witness significant growth rates.
Next generation vaccines such as edible plant-based vaccines could also have a significant impact on vaccines development.
New analysis from Frost & Sullivan, Analysis of the European Vaccines Market, finds that the European vaccines market earned revenues of $6.36 billion in 2011 and estimates this to reach $12.05 billion in 2018 at a compound annual growth rate (CAGR) of 9.6% from 2011-2018.
The high levels of unmet medical needs for diseases such as AIDS, malaria and tuberculosis - which affect millions of people every year and contribute to increasing healthcare expenditure - present huge growth potential and untapped market opportunities, thereby fuelling increased R&D investments and government support for vaccine development.
“The future growth of the vaccine industry is likely to be propelled by the adult vaccines segment,” notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram.
Chidambaram continued, “The tremendous success rates of the recently launched influenza and HPV vaccines have attracted the attention of market participants towards the adult vaccines. The vast majority of the vaccines in pipeline are novel, innovative vaccines based on new antigens, targeting malaria, tuberculosis, dengue fever, allergies and herpes.”
Anticipation of capacity demand remains a key challenge for vaccine manufacturers, particularly during pandemic outbreak of diseases.
“Speculation of vaccine production capacity considering unanticipated needs such as pandemic outbreaks, epidemics and bioterrorism is likely to have a huge impact on the growth and sustenance of vaccine manufacturers in Europe,” adds Chidambaram.
“Vaccine manufacturers are under the compulsion to maintain excess reserve supply owing to the tender-based vaccine procurement, lest they miss out on huge business opportunities.”
Accurate estimation of capacity demand and product differentiation will therefore be critical for market participants to garner a substantial share of the market.
“The highly fragmented nature of the European market will require market participants to accurately predict manufacturing capacity and fulfil global requirements during emergency situations, thereby enabling them to stay ahead of competition and prevent being hit by excess or inadequate capacity,” concludes Chidambaram.
SMi Presents the 2nd Annual Conference: Injectable Drug Delivery 2019
May 15 - May 16, 2019
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019